Biohaven Ltd.
BHVN · NYSE
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.15 | 0.17 | -0.16 | -0.57 |
| FCF Yield | -9.18% | -11.64% | -6.76% | -4.52% |
| EV / EBITDA | -9.95 | -7.49 | -10.89 | -19.80 |
| Quality | ||||
| ROIC | -56.23% | -48.68% | -73.00% | -40.55% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.84 | 0.85 | 0.74 | 0.91 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | 13.34% | -1.56% | 3.05% | -20.37% |
| Safety | ||||
| Net Debt / EBITDA | -0.72 | -0.60 | 0.29 | 0.33 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -1,424.61 | 0.00 | 0.00 | 0.00 |